| scholarly article | Q13442814 |
| P2093 | author name string | Birgit Spänkuch | |
| Lisa Lange | |||
| Juline Grigat | |||
| Sarah Keppner-Witter | |||
| P2860 | cites work | Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes | Q24312101 |
| Plk1-mediated phosphorylation of Topors regulates p53 stability | Q24314588 | ||
| Polo-like kinase 1 phosphorylation of G2 and S-phase-expressed 1 protein is essential for p53 inactivation during G2 checkpoint recovery | Q24336194 | ||
| Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors | Q24336470 | ||
| Plk1 promotes nuclear translocation of human Cdc25C during prophase | Q24522577 | ||
| GSK-3: tricks of the trade for a multi-tasking kinase | Q24624069 | ||
| Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells | Q24675189 | ||
| Polo-like kinases: a team in control of the division | Q28235650 | ||
| Polo-like kinases: a team that plays throughout mitosis | Q28292469 | ||
| Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors | Q29547463 | ||
| Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase | Q32165076 | ||
| Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer | Q33376116 | ||
| Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma | Q33710967 | ||
| Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs | Q33939126 | ||
| Polo-like kinases and oncogenesis | Q34382988 | ||
| Normal cells, but not cancer cells, survive severe Plk1 depletion | Q34519883 | ||
| BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. | Q34575151 | ||
| The isoform-specific regulation of apoptosis by protein kinase C. | Q35178042 | ||
| Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs | Q35640098 | ||
| An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells | Q36023740 | ||
| Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers | Q36625590 | ||
| Enzastaurin, an inhibitor of PKCbeta, Enhances Antiangiogenic Effects and Cytotoxicity of Radiation against Endothelial Cells | Q36970534 | ||
| The centrosome protein NEDD1 as a potential pharmacological target to induce cell cycle arrest | Q37116059 | ||
| Combination of enzastaurin and pemetrexed inhibits cell growth and induces apoptosis of chemoresistant ovarian cancer cells regulating extracellular signal-regulated kinase 1/2 phosphorylation | Q37313698 | ||
| Protein kinase Cbeta is an effective target for chemoprevention of colon cancer | Q37349308 | ||
| p53-Dependent and cell specific epigenetic regulation of the polo-like kinases under oxidative stress | Q39027006 | ||
| Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma | Q39264679 | ||
| Cyclotherapy: opening a therapeutic window in cancer treatment | Q39328882 | ||
| Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. | Q39593069 | ||
| Antitumor activity of enzastaurin as radiation sensitizer in head and neck squamous cell carcinoma. | Q39641088 | ||
| Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer | Q39687832 | ||
| Biological impact of freezing Plk1 in its inactive conformation in cancer cells | Q39742379 | ||
| Fate of primary cells at the G₁/S boundary after polo-like kinase 1 inhibition by SBE13. | Q39785377 | ||
| Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo | Q40272751 | ||
| The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway | Q40286322 | ||
| Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. | Q40447909 | ||
| Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function | Q40833387 | ||
| ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block | Q41150524 | ||
| Differential regulation of glycogen synthase kinase-3 beta by protein kinase C isotypes | Q41607785 | ||
| Polo-like kinase 1 (Plk1) in non-melanoma skin cancers | Q42111415 | ||
| Inhibition of glycogen synthase kinase-3 increases the cytotoxicity of enzastaurin | Q42759595 | ||
| Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1. | Q44226599 | ||
| Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. | Q44918126 | ||
| Ataxia-telangiectasia mutated (ATM)-dependent activation of ATR occurs through phosphorylation of TopBP1 by ATM. | Q46202457 | ||
| The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts | Q46652649 | ||
| Synergistic antiglioma activity of radiotherapy and enzastaurin | Q48315412 | ||
| p53 Suppresses E2F1-dependent PLK1 expression upon DNA damage by forming p53-E2F1-DNA complex. | Q51528185 | ||
| Targeting polo-like kinase 1 for cancer therapy. | Q53348000 | ||
| Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1. | Q53371760 | ||
| Plk1-dependent phosphorylation regulates functions of DNA topoisomerase IIalpha in cell cycle progression. | Q53507575 | ||
| Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer | Q64449297 | ||
| Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells | Q74355620 | ||
| Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs | Q74737230 | ||
| Polo-like kinase (Plk) 1: a novel target for the treatment of prostate cancer | Q75244856 | ||
| Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells | Q78680328 | ||
| The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1 | Q79754843 | ||
| Rational combinations of siRNAs targeting Plk1 with breast cancer drugs | Q79976833 | ||
| Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma | Q84439864 | ||
| Enzastaurin | Q94700480 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2263-2275 | |
| P577 | publication date | 2014-04-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Combinatorial inhibition of Plk1 and PKCβ in cancer cells with different p53 status | |
| P478 | volume | 5 |
| Q34956519 | A novel DAG-dependent mechanism links PKCɑ and Cyclin B1 regulating cell cycle progression |
| Q38902467 | Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status |
| Q37708943 | Impact of Polo-like kinase 1 inhibitors on human adipose tissue-derived mesenchymal stem cells |
| Q36780701 | Inhibition of polo like kinase 1 in sarcomas induces apoptosis that is dependent on Mcl-1 suppression |
Search more.